Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Low mutation percentage of KRAS and BRAF genes in Brazilian anal tumors

Full text
Author(s):
Show less -
Bidinotto, Lucas Tadeu ; Veo, Carlos A. R. ; Loaiza, Edgar Aleman ; Santos De Franca, Alessandra Paulino ; Lorenzi, Adriana Tarla ; Reis Rosa, Luciana Albina ; De Oliveira, Cristina Mendes ; Levi, Jose Eduardo ; Scapulatempo-Neto, Cristovam ; Longatto-Filho, Adhemar ; Reis, Rui Manuel
Total Authors: 11
Document type: Journal article
Source: MOLECULAR MEDICINE REPORTS; v. 14, n. 4, p. 3791-3797, OCT 2016.
Web of Science Citations: 1
Abstract

Anal cancer is a rare type of digestive tract disease, which has had a crescent incidence in a number of regions. Carcinomas are most frequently found, with squamous cell carcinoma (SCC) comprising similar to 95% of all anal tumors. The major risk factor for development of this type of tumor is human papillomavirus (HPV) infection. However, previous studies have identified patients with anal cancer that are HPV-/p16-and observed that they have a poorer outcome compared with HPV+/p16+ patients. This suggests that molecular profile may drive anal cancer progression. The aim of the present study was to evaluate the mutational status of two important oncogenes, KRAS and BRAF, in a series of anal cancer lesions. Resected tumors of the anal canal (n=43) were evaluated, nine of these were high-grade squamous intra-epithelial lesion cases (HSIL), 11 were adenocarcinomas, and 23 SCCs. Direct sequencing of KRAS proto-oncogene, GTPase (KRAS; codons 12 and 13) and B-Raf proto-oncogene, serine/threonine kinase (BRAF; codon 600) was performed and associated with patient clinicopathological and molecular features. There was a trend of poorer prognosis of adenocarcinoma compared with HSIL and SCC. Analysis indicated one SCC patient (2.3%) exhibited a KRAS p.G13D mutation, and one adenocarcinoma patient (2.3%) exhibited a BRAF p.V600E mutation. It was observed that, these mutations are rare in anal tumors, and certain patients may be at a disadvantage using targeted therapies based on KRAS and BRAF mutational status. As there is a low mutation percentage in SCCs, adenocarcinomas and HSIL, there may exist other underlying molecular alterations that result in anal cancer development, which require further elucidation. (AU)

FAPESP's process: 10/16795-4 - HPV biomarkers screening in anal swab: correlation with cervix, oral and oropharyngeal infections
Grantee:Adhemar Longatto Filho
Support type: Regular Research Grants
FAPESP's process: 11/08523-7 - Chromosomal alterations profiling in brain tumors (medulloblastomas and gliomas): the impact in the identification of new tumorigenic pathways
Grantee:Lucas Tadeu Bidinotto
Support type: Scholarships in Brazil - Post-Doctorate